Biotech Pharmaceutical Co., Ltd.
Quick facts
Marketed products
- Nimotuzumab Injection · Oncology
Nimotuzumab is a humanized monoclonal antibody that blocks the epidermal growth factor receptor (EGFR) to inhibit tumor cell proliferation and survival. - painkiller · Pain
Phase 3 pipeline
- nimotuzumab plus paclitaxel · Oncology
Nimotuzumab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR), while paclitaxel is a taxane that inhibits cell division. - placebo plus chemoradiotherapy · Oncology
This drug works by combining a placebo with chemoradiotherapy to treat cancer. - placebo plus paclitaxel · Oncology
Paclitaxel works by inhibiting cell division, thereby preventing cancer cells from growing and spreading.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: